Caliway Biopharmaceuticals Co. L
6919
Clasificación en acciones
#4343
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Precio por acción
$2.29
Capitalización bursátil
$3.56B
Cambio (1 día)
-2.50%
Cambio (1 año)
-57.22%
País
TW
Comercio Caliway Biopharmaceuticals Co. L (6919)
Categoría
Healthcare
Historial de rendimiento por dividendo de Caliway Biopharmaceuticals Co. L (6919)
Rendimiento por dividendo (TTM) de Caliway Biopharmaceuticals Co. L (símbolo bursátil: 6919) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Caliway Biopharmaceuticals Co. L (6919) desde 2025 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
| Año | Rendimiento por dividendo | Cambiar |
|---|---|---|
| 2025 | 0.00% | 0.00% |
Rendimientos por dividendo (TTM) de empresas similares o competidoras
| Empresa | Rendimiento por dividendo | País |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
